Jiangsu Voncolytic Therapeutics Co., Ltd. (V Therapeutics) is a core subsidiary of Wanbang Biopharmaceuticals (Group) (hereinafter referred to as Wanbang Biopharma). With clinical demand of science and technology as the guidance, it focuses on the field of gene therapy and on a new generation of oncolytic virus, antitumor drugs and therapeutic gene therapy of tumor vaccine development. It actively builds gene therapy platform with independent intellectual property rights and core competitiveness, committed to become the international R&D enterprise driven by innovation, and continue to launch innovative gene therapy products with clinical advantages and market value.